The Wall Street Journal: As Dry January grows in popularity, the $17 mocktail becomes a reality
Bartenders are getting ever more creative with non-alcoholic drinks. A Curried Corn cocktail, anyone?
: FDA approves treatment for people with mild forms of Alzheimer’s
Leqembi, which was developed by Eisai and Biogen, will cost about $26,000 a year
: Imported baby formula is about to get expensive again, with tariffs back in place
Product recalls from Abbott Laboratories last February exacerbated an infant-formula shortage caused by supply-chain disruptions.
Vitaliy Katsenelson’s Contrarian Edge: SBF and FTX peddled a crypto fraud that makes scammer Bernie Madoff look like an amateur
Crypto market's collapse exposes a giant, unregulated casino, hijacked by greed.
: Kevin McCarthy elected House speaker, narrowly prevailing in 15th round of voting
Top House Republican Kevin McCarthy wins in his push to become the next speaker, claiming the job after first falling short in multiple rounds of...
: Redfin CEO predicts ‘terrible consolidation’ in the real-estate sector, but says it will ultimately be good for the industry
The real-estate sector is in crisis amid the housing downturn. Expect more pain to come before things start to normalize, one housing chief says.
: AbbVie cuts earnings forecast due to milestone payments
AbbVie Inc. lowered its outlook for the quarter and year late Friday for research and development expenses and milestone payments to partners.
: FTC’s proposed ban on noncompete agreements could have biggest impact on tech industry
A proposed FTC ban on noncompete agreements would apply across all industries and income levels, but could have the biggest impact on the tech industry.
: Macy’s stock slides as holiday lulls weigh on sales forecast and execs predict difficulties into 2023
Macy's stock falls as much as 8% in after-hours trading on Friday after the retailer gives a more downbeat forecast on its fourth-quarter sales.